Anti-Aging Stack

Aging isn't one clock — geroscience counts at least a dozen, ticking at different speeds and responding to different interventions. The Anti-Aging Stack selects three that rarely get addressed together: Epithalon, a synthetic tetrapeptide studied for reactivating telomerase — the enzyme maintaining chromosome ends — in somatic cells that have normally silenced it [PMID: 12398480]; GHK-Cu, a naturally occurring copper-binding tripeptide whose plasma decline tracks with collagen loss and fading antioxidant defenses [PMID: 26236730]; and NAD+, an essential coenzyme fueling sirtuins, PARP repair enzymes, and mitochondrial electron transport [PMID: 24786309, 31065944].

The selection principle is deliberate non-overlap: chromosomal erosion, structural degradation of tissue architecture, and bioenergetic decline are separate hallmarks of biological aging addressed by separate mechanisms. A reader who noticed grayer hair, slower recovery, and fading stamina within the same year has watched all three clocks running simultaneously — which is exactly why single-compound approaches feel incomplete.

Ahead you'll find what each compound's research actually shows, how the layers stack conceptually, and where evidence thins out — mostly preclinical work, with early-stage human trials only for NAD+ precursors. No regulator has approved any such combination; that context frames everything below.

Epithalon takes the chromosomal layer. Research suggests the tetrapeptide may reactivate telomerase reverse transcriptase (hTERT) in somatic cells, potentially extending replicative lifespan [PMID: 12398480], and animal studies report mean lifespan extension associated with chronic epitalon administration [PMID: 15865243]. A quieter circadian thread runs through the data too: research indicates restoration of age-declined nocturnal melatonin secretion through pinealocyte resensitization, addressing the circadian disruption common in aging populations [PMID: 10709557].

GHK-Cu takes the architectural layer — and its own trajectory mirrors aging. Plasma concentrations fall from approximately 200 ng/mL in young adults toward near-undetectable levels in older individuals [PMID: 29986520]. Studies suggest stimulated fibroblast production of collagen and elastin, the structural proteins maintaining skin firmness and connective tissue integrity [PMID: 26236730], alongside upregulated antioxidant defense genes including superoxide dismutase — a gene-regulatory approach to oxidative stress rather than passive radical scavenging [PMID: 26236730]. Angiogenesis promotion adds a vascular dimension relevant to tissue repair and nutrient delivery [PMID: 29986520].

NAD+ takes the metabolic-genomic layer. The coenzyme fuels sirtuin family deacetylases (SIRT1–7), regulators of mitochondrial function, metabolic homeostasis, and stress response pathways [PMID: 24786309], and feeds PARP-1/PARP-2 enzymes racing to repair accumulating DNA strand breaks [PMID: 31065944]. Why levels fall has a prime suspect: CD38 glycohydrolase expression rises in aging tissues, steadily draining cellular NAD+ pools [PMID: 26785480]. Because sirtuins and PARPs draw on the same pools, this slow drain compounds across maintenance systems [PMID: 26785480].

Three compounds, three non-communicating compartments of the aging process. The synergy case rests on coherence rather than chemistry — and it remains untested, since no study has combined all three. The protocol realities ahead show how differently each clock wants to be read.

Three compounds, three delivery philosophies — reconciling them is the practical challenge of this stack. Epithalon is studied primarily via subcutaneous injection at 5–10 mg per day in short courses of roughly 10 days, repeated every few months [PMID: 15865243] — a pulsatile approach reflecting the hypothesis that brief telomerase activation triggers sustained transcriptional change without requiring continuous exposure. Its plasma half-life runs minutes; its biological effects evidently don't. Intranasal delivery has been explored but lacks standardized dosing protocols.

GHK-Cu research uses both topical routes (0.1–1% dermatological formulations targeting skin-specific endpoints like collagen synthesis and wound healing) and subcutaneous delivery aimed at systemic tissue remodeling effects [PMID: 26236730]. Its short plasma half-life necessitates repeated administration for sustained exposure, and formulation chemistry matters considerably here — pH, solvent, and penetration enhancers significantly affect the bioavailability of this copper-binding peptide.

NAD+ is studied almost entirely through oral precursors rather than direct administration: clinical trials exploring nicotinamide riboside at 100–2000 mg/day and nicotinamide mononucleotide at 250–900 mg/day, both showing dose-dependent elevation of blood NAD+ levels [PMID: 29184669, 32320006, 36482258]. Human replication extends across independent precursor trials [PMID: 36482258]. Direct IV or subcutaneous NAD+ appears in research settings but lacks the trial infrastructure of precursors.

Combining all three means reconciling pulsatile injection courses, regular topical or injectable administration, and daily oral supplementation. No consensus combined protocol exists; every figure here is an independent reference point, not a recipe — which frames the questions ahead.